FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine and concerns modelling osteoporosis. That is ensured by oophorectomy in a laboratory animal. Then omeprazole is administered in a dosage 0.3-0.4 mg/kg orally within 6 months.
EFFECT: higher accuracy of modelling osteoporosis caused by inhibitors of proton pump.
3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR INTRAHEPATIC CHOLESTASIS | 2008 |
|
RU2386134C1 |
| METHOD FOR PREDICTION OF PROGRESSION OF HEPATIC FAILURE IN INTRAHEPATIC CHOLESTASIS | 2008 |
|
RU2372619C1 |
| METHOD FOR MODELING PYLOROSTENOSIS | 2006 |
|
RU2321075C1 |
| METHOD OF SYSTEMIC FIBROSIS MODELLING | 2008 |
|
RU2371778C1 |
| METHOD FOR PREVENTION OF GASTROESOPHAGEAL REFLUX | 2008 |
|
RU2388066C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSTICS OF CHRONIC HEPATITIS AND CIRRHOSIS AT HEPATOCEREBRAL DYSTROPHY | 2005 |
|
RU2287165C1 |
| METHOD FOR MODELING NONSPECIFIC ULCERATIVE COLITIS CASES | 2006 |
|
RU2316055C1 |
| METHOD OF DIAGNOSING CHRONIC LIVER DISEASES CAUSED BY POLYVIRAL INFECTION | 2011 |
|
RU2496426C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR LIVER DISEASES OF VARIOUS AETIOLOGIES ACCOMPANIED WITH INTRAHEPATIC CHOLESTASIS | 2008 |
|
RU2386969C2 |
| METHOD FOR HEPATIC FIXATION AT NARCOTIZED ANIMAL'S LIFE PERIOD | 2004 |
|
RU2269110C2 |
